ReShape Lifesciences — EnteroMedics — IPO Roadshow (December 2016)
31 slides from ReShape Lifesciences's IPO roadshow presentation, Dec 30, 2016
Slide 1: Investor Presentation January 2017
Investor Presentation January 2017 NASDAQ: ETRM www.enteromedics.com Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated December 29, 2016 Relating to Preliminary Prospectus dated December 29, 2016 Registration No. 333-213704
Slide 2: Safe Harbor Statement and Risk Factors
Safe Harbor Statement and Risk Factors This presentation contains forward-looking statements about EnteroMedics Inc. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and
Slide 3: Statement about Free Writing Prospectus
Statement about Free Writing Prospectus This presentation highlights basic information about us and the offering. Because it is a summary that has been prepared solely for informational purposes, it does not contain all of the information that you should consider before investing in our company. Exc
Slide 4: Why invest in Enteromedics?
Why invest in Enteromedics? Growth of obesity is outpacing the surgical interventions “The prevalence of obesity was 36% among U.S. adults during 2011 – 2014” ~$3 Billion Surgical Market ~200,000 Procedures Annually Only ~1% of Obese Seek Treatment Proven management team FDA approved and CE marked p
Slide 5: Company Overview Management Team
Company Overview Management Team
Slide 6: Company Overview
Company Overview EnteroMedics Inc. is a medical device company, headquartered in St. Paul, MN, focused on the development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. ETRM’s proprietary neuroblocking technology, vBloc® Therap
Slide 7: Executive Leadership
Executive Leadership New executive leadership brings seasoned experience in creating shareholder value. Dan W. Gladney – Chairman, President, and Chief Executive Officer CEO and Chairman of the Board at Lanx, Inc., which was acquired by EBI Holdings, LLC Senior Advisor and Healthcare Operating Partn
Slide 8: Chief Financial Officer and management team
Scott P. Youngstrom – Chief financial officer Financial executive focused on creating shareholder value with 25 years of strategic financial and operational experience in a variety of medical device companies Galil Medical, Anulex, Enpath Medical, Compex Technologies PAUL F. HICKEY – VICE PRESIDENT,
Slide 9: Board of Directors
GARY D. BLACKFORD Former Chief Executive Officer, Universal Hospital Services Former Chief Executive Officer, Curative Health Services, Inc. Chair, Nominating & Governance Committee LORI C. MCDOUGAL Former Executive Vice President of Optum, Inc. Former Chief Executive Officer, Unitedhealthcare Milit
Slide 10: Understanding vBloc
a MBloc neurometabolic therapy Understanding vBloc® EnterMediics
Slide 11: Competitive Procedures
Competitive Procedures Temporary and must be removed Inconsistently effective Anatomy restricting Irreversible anatomy changes Very restrictive diet for lifetime Potential for serious complications BALLOON (~$8,000 procedure cost) BAND (~$15,000 procedure cost) SLEEVE (~$19,000 procedure cost) BY-PA
Slide 12: vBloc Advantages
Non-anatomy altering procedure Minimally invasive outpatient procedure Lower complication rate Patient eats normal food Durable life-long therapy Improved quality of life vBloc® Advantages vBloc
Slide 13: vBloc Advantages: FDA Approved, Patient Eligibility
(1) Center for Disease Control (CDC) vBloc Advantages FDA Approved Patient Eligibility BMI of 35 – 39.9 with health-related conditions BMI of 40 – 45 ~700 Implanted Devices Worldwide Clinical Data Highlights vBloc Therapy as a Leader in Clinical Safety
Slide 14: How vBloc Therapy Works
Neurometabolic Therapy 2 leads connected to the vagus nerve to block hunger signals between brain + stomach Customizable for every Patient Therapy delivered up to 18 hours per day Can adjust level of blocking intensity Can be turned on and off or removed (e.g. pregnancy) Recharged wirelessly by Pati
Slide 15: Market
a MBloc neurometabolic therapy Market EnterMediics
Slide 16: U.S. Obesity Market – Large Underserved Market
U.S. Obesity Market – Large Underserved Market 2015 U.S. Population 18-80 years old ~ 220 million* U.S. Population with BMI 35-45 ~ 18% or 40 million (potential vBloc Patients) Procedures Done In 2015 ~ 196,000** Less invasive device market growth projection > 30% yr/yr** *www.census.gov **American
Slide 17: Obesity Related Diseases are Costly
Obesity Related Diseases are Costly Payer Obesity Concerns According to the World Health Organization, there are over 70 progressive obesity-related diseases and disorders including Type II Diabetes. ~44% of the global diabetes burden is attributable to overweight and obesity. Employer Obesity Conce
Slide 18: Public Markets
Public Markets Apollo Endosurgery, Inc. obesity treatment products include the Orbera Intragastric Balloon System and Lap-Band System. Apollo is in the process of a reverse merger with Lpath, Inc. (NASDAQ:LPATH) Obalon Therapeutics, Inc. (NASDAQ:OBLN) offers the Obalon balloon system Market Cap. (Pu
Slide 19: Commercialization
a MBloc neurometabolic therapy Commercialization EnterMediics
Slide 20: How Will We Win? 2017 Commercialization Strategies
How Will We Win? 2017 Commercialization Strategies Establish vBloc as a standard of care for Veterans within the U.S. VA System with a focused Direct-to-Patient marketing effort. Obtain favorable commercial payer and/or Medicare Administrator Contractor Coverage Expand our number of vBloc Institutes
Slide 21: vBloc Therapy covered benefit for U.S. veterans
vBloc Therapy is a covered benefit for over 21 million U.S. veterans Marketing lead generation programs directed toward veterans e-mail campaign, social media Qualified leads sent to facility/surgeon Trained VA surgeon Registered vBloc “Choice Program” surgeon (1) U.S. Department of Veterans Affairs
Slide 22: Obtain vBloc Reimbursement
Our reimbursement strategy is multi-faceted and will drive long-term coverage. Clinical Data – Continue to publish efficacy, and safety data Cost Savings – Publish pharmacoeconomic savings and complication reduction costs Physician Demand – vBloc surgeons are actively engaging commercial payers and
Slide 23: Expand Our vBloc Commercial Sites
Fountain Valley, CA Charleston, SC Galveston, TX Denver, CO Newark, DE Atlanta, GA New York, NY Expand Our vBloc Commercial Sites Institute Obligations Data collection/publication Employee coverage (where applicable) Payer and employer engagement vBloc marketing programs EnteroMedics’ Obligations vB
Slide 24: Sales Team Expansion
Sales Team Expansion Clinically focused sales organization supporting vBloc physicians, weight-management specialists and nurses Position 2016 Focus Sales 4 Lead Sales support effort for vBloc Institutes and VA’s Field Clinical Specialist 3 Clinical support for surgeries and vBloc aftercare Canadian
Slide 25: Clinical Data
a MBloc neurometabolic therapy Clinical Data EnterMediics
Slide 26: Clinical publication references
Camilleri, Michael, et al. “Intra-abdominal Vagal Blocking (VBLOC Therapy): Clinical Results with a New Implantable Medical Device. Surgery.” Journal of the Society of University Surgeons 143 (2008):723-731. Print. Camilleri, Michael, et al. “Selection of Electrical Algorithms to Treat Obesity with
Slide 27: Clinical Data: ReCharge FDA Trial Results
Clinical Data Mean %TBL ReCharge Sham ReCharge ReCharge Moderate BMI DM2 With ReCharge, the Sham patients lost more than expected, but regained nearly all weight by 18 months. Months Follow-Up Caroline M. Apovian & Sajani N. Shah & Bruce M. Wolfe & Sayeed Ikramuddin & Christopher J. Miller & Katheri
Slide 28: Risk factor improvements with 10% weight loss
Risk Factor 1 Year Follow-up Outcomes with 10% Total Body Weight Loss Health Improvement Observed HbA1c (%) (Diabetes Trial) -1.0 Clinically significant improvement in diabetic health Waist Circumference (reduction in inches) -7” Reduction of abdominal fat, the fat associated with CV disease Triglyc
Slide 29: Winthrop University vBloc Patient Success Story
12 months of vBloc Therapy Lost 75 lbs* (~27% TBL) Off Insulin 100% Stopped Taking Several Other Medications Estimated $15,000 Annual Savings Reported by Patient "This new technology aligns with our mission to provide high quality, safe and comprehensive healthcare, while also helping to address the
Slide 30: Clinical Data: Commercial vBloc Results
Clinical Data Mean %TBL Number of Patients at Follow-up Data on file at EnteroMedics 1-3 Months 6 Month (+/-1) 9 Month (+/-2) vBloc + Achieve – Commercial Data 35 26 15 ReCharge (FDA) ReCharge Moderate BMI Commercial + vAchieve* 10% Commercial vBLOC Results Compared to ReCharge (%TBL at 9 Months) 7.
Slide 31: EnteroMedics Inc. contact details
EnteroMedics Inc. (NASDAQ:ETRM) 2800 Patton Road St. Paul, MN 55113 Dan Gladney Chairman & Chief Executive Officer 651-634-3089 [email protected]